Literature DB >> 16892375

Drugs targeting protein-protein interactions.

Patrick Chène1.   

Abstract

Most biological processes involve permanent and nonpermanent interactions between different proteins, and many protein complexes play a key role in various human diseases. Therefore, molecules that prevent the formation of these protein complexes could be valuable new therapeutic agents to treat these diseases. Protein interfaces have not evolved to bind low-molecular-weight molecules, as is the case with enzyme catalytic sites. It is therefore difficult to identify small compounds that inhibit protein-protein interactions. However, there is considerable diversity in the structure of protein interfaces, some of which may be more attractive than others for medicinal chemistry. One of the main challenges in drug discovery is to identify these interfaces and to exploit their properties to make marketable drugs. Herein, the properties of protein interfaces are discussed in light of their use as drug targets.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16892375     DOI: 10.1002/cmdc.200600004

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  33 in total

1.  Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic.

Authors:  Sashikanth Banappagari; Miriam Corti; Seth Pincus; Seetharama Satyanarayanajois
Journal:  J Biomol Struct Dyn       Date:  2012-06-26

2.  Medicinal chemistry for 2020.

Authors:  Seetharama D Satyanarayanajois; Ronald A Hill
Journal:  Future Med Chem       Date:  2011-10       Impact factor: 3.808

3.  Conformationally constrained peptides from CD2 to modulate protein-protein interactions between CD2 and CD58.

Authors:  Ameya Gokhale; Thomas K Weldeghiorghis; Veena Taneja; Seetharama D Satyanarayanajois
Journal:  J Med Chem       Date:  2011-07-14       Impact factor: 7.446

Review 4.  Ligand discovery and virtual screening using the program LIDAEUS.

Authors:  P Taylor; E Blackburn; Y G Sheng; S Harding; K-Y Hsin; D Kan; S Shave; M D Walkinshaw
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

Review 5.  Knitting and untying the protein network: modulation of protein ensembles as a therapeutic strategy.

Authors:  Susana Gordo; Ernest Giralt
Journal:  Protein Sci       Date:  2009-03       Impact factor: 6.725

6.  Computer aided design of FtsZ targeting oligopeptides.

Authors:  Stefano Rendine; Chacko Jobichen; Stefano Pieraccini; Prerna Domadia; J Sivaraman; Pierangelo Francescato; Giovanna Speranza; Maurizio Sironi
Journal:  RSC Adv       Date:  2012-12-21       Impact factor: 3.361

7.  In silico design of tubulin-targeted antimitotic peptides.

Authors:  Stefano Pieraccini; Giorgio Saladino; Graziella Cappelletti; Daniele Cartelli; Pierangelo Francescato; Giovanna Speranza; Paolo Manitto; Maurizio Sironi
Journal:  Nat Chem       Date:  2009-10-23       Impact factor: 24.427

8.  Structure-based design of small peptide inhibitors of protein kinase CK2 subunit interaction.

Authors:  Béatrice Laudet; Caroline Barette; Vincent Dulery; Olivier Renaudet; Pascal Dumy; Alexandra Metz; Renaud Prudent; Alexandre Deshiere; Otto Dideberg; Odile Filhol; Claude Cochet
Journal:  Biochem J       Date:  2007-12-15       Impact factor: 3.857

9.  Template-constrained macrocyclic peptides prepared from native, unprotected precursors.

Authors:  Kenneth V Lawson; Tristan E Rose; Patrick G Harran
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

10.  Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α.

Authors:  Dennis L Buckley; Jeffrey L Gustafson; Inge Van Molle; Anke G Roth; Hyun Seop Tae; Peter C Gareiss; William L Jorgensen; Alessio Ciulli; Craig M Crews
Journal:  Angew Chem Int Ed Engl       Date:  2012-10-12       Impact factor: 15.336

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.